Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease

References

1. • Estes C.
   • Anstee Q.M.
   • Arias-Loste M.T.
   • et al.
   Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
   J Hepatol. 2018; 69: 896-904
   View in Article

   • Google Scholar
2. • Dulai P.S.
   • Singh S.
   • Patel J.
   • et al.
   Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis.
   Hepatology. 2017; 65: 1557-1565
   View in Article

   • Google Scholar
3. • Younossi Z.
   • Stepanova M.
   • Ong J.P.
   • et al.
   Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates.
   Clin Gastroenterol Hepatol. 2019; 17 (e3): 748-755
   View in Article

   • Google Scholar
4. • Romeo S.
   • Kozlitina J.
   • Xing C.
   • et al.
   Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.
   Nat Genet. 2008; 40: 1461-1465
   View in Article

   • Google Scholar
5. • Chen L.Z.
   • Xia H.H.X.
   • Xin Y.N.
   • Lin Z.H.
   • Xuan S.Y.
   TM6SF2 E167K variant, a novel genetic susceptibility variant, contributing to nonalcoholic fatty liver disease.
   J Clin Transl Hepatol. 2015; 3: 265-270
   View in Article

   • Google Scholar
6. • Dongiovanni P.
   • Romeo S.
   • Valenti L.
   Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis.
   Biomed Res Int. 2015; 2015: 460190
   View in Article

   • Google Scholar
7. • Bianco C.
   • Jamialahmadi O.
   • Pelusi S.
   • et al.
   Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
   J. Hepatol. 2021; 74: 775-782
   View in Article

   • Google Scholar
8. • Calle E.E.
   • Rodriguez C.
   • Walker-Thurmond K.
   • Thun M.J.
   Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.
   N Engl J Med. 2003; 348: 1625-1638
   View in Article

   • Google Scholar
9. • El-Serag H.B.
   • Tran T.
   • Everhart J.E.
   Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma.
   Gastroenterology. 2004; 126: 460-468
   View in Article

   • Google Scholar
10. • Zoppini G.
    • Fedeli U.
    • Gennaro N.
    • Saugo M.
    • Targher G.
    • Bonora E.
    Mortality from chronic liver diseases in diabetes.
    Am J Gastroenterol. 2014; 109: 1020-1025
    View in Article

    • Google Scholar
11. • Margini C.
    • Dufour J.F.
    The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment.
    Liver Int. 2016; 36: 317-324
    View in Article

    • Google Scholar
12. • Kulik L.
    • El-Serag H.B.
    Epidemiology and management of hepatocellular carcinoma.
    Gastroenterology. 2019; 156: 477-491
    View in Article

    • Google Scholar
13. • Kim D.
    • Li A.A.
    • Perumpail B.J.
    • et al.
    Changing trends in etiology-based and ethnicity-based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States.
    Hepatology. 2019; 69: 1064-1074
    View in Article

    • Google Scholar
14. • Reig M.
    • Gambato M.
    • Man N.K.
    • et al.
    Should patients with NAFLD/NASH be surveyed for HCC?.
    Transplantation. 2019; 103: 39-44
    View in Article

    • Google Scholar

15. J.G. Stine, B.J. Wentworth, A. Zimmet, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018;48(7):696–703.

    View in Article

    • Google Scholar
16. • Piscaglia F.
    • Svegliati-Baroni G.
    • Barchetti A.
    • et al.
    Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study.
    Hepatology. 2016; 63: 827-838
    View in Article

    • Google Scholar
17. • Younossi Z.M.
    • Otgonsuren M.
    • Henry L.
    • et al.
    Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.
    Hepatology. 2015; 62: 1723-1730
    View in Article

    • Google Scholar

18. M. Alexander, D. Ansell, A. Pasqua, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Medicine 2019;17:19.

    View in Article

    • Google Scholar
19. • Angulo P.
    • Kleiner D.E.
    • Dam-Larsen S.
    • et al.
    Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.
    Gastroenterology. 2015; 149 (--): 389-397
    View in Article

    • Google Scholar
20. • Vilar-Gomez E.
    • Calzadilla-Bertot L.
    • Wong V W.S.
    • et al.
    Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study.
    Gastroenterology. 2018; 155 (--): 443-457
    View in Article

    • Google Scholar
21. • Pelusi S.
    • Cespiati A.
    • Rametta R.
    • et al.
    Prevalence and risk factors of significant fibrosis in patients with nonalcoholic fatty liver without steatohepatitis.
    Clin Gastroenterol Hepatol. 2019; 17 (--): 2310-2319
    View in Article

    • Scopus (57)
    • Abstract
    • Full Text
    • Full Text PDF
    • Google Scholar
22. • Simon T.G.
    • King L.Y.
    • Chong D.Q.
    • et al.
    Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies.
    Hepatology. 2018; 67: 1797-1806
    View in Article

    • Google Scholar
23. • Kanwal F.
    • Kramer J.R.
    • Li L.
    • et al.
    Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease.
    Hepatology. 2020; 71: 808-819
    View in Article

    • Google Scholar
24. • Hassan M.M.
    • Kaseb A.
    • Li D.
    • et al.
    Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States.
    Hepatology. 2009; 49: 1563-1570
    View in Article

    • Google Scholar
25. • Trépo E.
    • Valenti L.
    Update on NAFLD genetics: from new variants to the clinic.
    J Hepatol. 2020; 72: 1196-1209
    View in Article

    • Google Scholar
26. • Donati B.
    • Dongiovanni P.
    • Romeo S.
    • et al.
    MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.
    Sci Rep. 2017; 7: 4492
    View in Article

    • Google Scholar
27. • Romeo S.
    • Sanyal A.
    • Valenti L.
    Leveraging human genetics to identify potential new treatments for fatty liver disease.
    Cell Metab. 2020; 31: 35-45
    View in Article

    • Google Scholar
28. • Pelusi S.
    • Valenti L.
    Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease.
    Liver Int. 2019; 39: 250-256
    View in Article

    • Google Scholar
29. • European Association for the Study of the Liver. Electronic address: [email protected], European Association for the Study of the Liver
    EASL clinical practice guidelines: management of hepatocellular carcinoma.
    J Hepatol. 2018; 69: 182-236
    View in Article

    • Google Scholar
30. • Liu Y.L.
    • Patman G.L.
    • Leathart J.B.S.
    • et al.
    Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.
    J Hepatol. 2014; 61: 75-81
    View in Article

    • Google Scholar
31. • Anstee Q.M.
    • Liu Y.L.
    • Day C.P.
    • Reeves H.L.
    Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance.
    J Hepatol. 2015; 62: 982-983
    View in Article

    • Google Scholar
32. • Krawczyk M.
    • Stokes C.S.
    • Romeo S.
    • Lammert F.
    HCC and liver disease risks in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance.
    J Hepatol. 2015; 62: 980-981
    View in Article

    • Google Scholar
33. • Font-Burgada J.
    • Sun B.
    • Karin M.
    Obesity and cancer: the oil that feeds the flame.
    Cell Metab. 2016; 23: 48-62
    View in Article

    • Google Scholar
34. • Ibrahim S.H.
    • Hirsova P.
    • Gores G.J.
    Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.
    Gut. 2018; 67: 963-972
    View in Article

    • Google Scholar
35. • Luedde T.
    • Beraza N.
    • Kotsikoris V.
    • et al.
    Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma.
    Cancer Cell. 2007; 11: 119-132
    View in Article

    • Google Scholar
36. • Grohmann M.
    • Wiede F.
    • Dodd G.T.
    • et al.
    Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.
    Cell. 2018; 175: 1289-1306
    View in Article

    • Google Scholar
37. • Kettner N.M.
    • Voicu H.
    • Finegold M.J.
    • et al.
    Circadian homeostasis of liver metabolism suppresses hepatocarcinogenesis.
    Cancer Cell. 2016; 30: 909-924
    View in Article

    • Google Scholar
38. • Ponziani F.R.
    • Bhoori S.
    • Castelli C.
    • et al.
    Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease.
    Hepatology. 2019; 69: 107-120
    View in Article

    • Google Scholar
39. • Boursier J.
    • Mueller O.
    • Barret M.
    • et al.
    The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.
    Hepatology. 2016; 63: 764-775
    View in Article

    • Google Scholar
40. • Miele L.
    • Valenza V.
    • La Torre G.
    • et al.
    Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease.
    Hepatology. 2009; 49: 1877-1887
    View in Article

    • Google Scholar
41. • Grąt M.
    • Wronka K.M.
    • Krasnodębski M.
    • et al.
    Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis.
    Transplant Proc. 2016; 48: 1687-1691
    View in Article

    • Google Scholar
42. • Henao-Mejia J.
    • Elinav E.
    • Jin C.
    • et al.
    Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.
    Nature. 2012; 482: 179-185
    View in Article

    • Google Scholar

43. S. Mittal, H.B. El-Serag, Y.H. Sada, et al. Hepatocellular carcinoma in the absence of cirrhosis in US veterans is associated with non-alcoholic fatty liver disease. 2016;14:124–31.

    View in Article

    • Google Scholar
44. • Natarajan Y.
    • Kramer J.R.
    • Yu X.
    • et al.
    Risk of cirrhosis and hepatocellular cancer in patients with NAFLD and normal liver enzymes.
    Hepatology. 2020; 72: 1242-1252
    View in Article

    • Google Scholar
45. • Younossi Z.M.
    • Koenig A.B.
    • Abdelatif D.
    • et al.
    Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes.
    Hepatology. 2016; 64: 73-84
    View in Article

    • Google Scholar
46. • Stine J.G.
    • Wentworth B.J.
    • Zimmet A.
    • et al.
    Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.
    Aliment Pharmacol Ther. 2018; 48: 696-703
    View in Article

    • Google Scholar

47. Taylor R.S., Taylor R.J., Bayliss S., et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis 2020;158:1611–1625.

    View in Article

    • Google Scholar
48. • Marin V.
    • Rosso N.
    • Ben M.D.
    • et al.
    An animal model for the juvenile non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    PLoS ONE. 2016; 11: 1-15
    View in Article

    • Google Scholar

49. O'Hara J., Finnegan A., Dhillon H., et al. Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study. J HEP 2020;2(5):18. 2100142. doi:10.1016/j.jhepr.2020.100142. eCollection 2020 Oct.

    View in Article

    • Google Scholar

50. Tapper E.B., Hunink M.G.M., Afdhal N.H., Lai M., Sengupta N.et al. Cost-effectiveness analysis: risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score. PLoS ONE 2016;11(2):112. e0147237. doi:10.1371/journal.pone.0147237. eCollection 2016.

    View in Article

    • Google Scholar
51. • Simon T.G.
    • Roelstraete B.
    • Sharma R.
    • Khalili H.
    • Hagström H.
    • Ludvigsson J.F.
    Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: a population-based cohort study.
    Hepatology. 2021;
    View in Article

    • Google Scholar

52. V. Paradis, S. Zalinski, E. Chelbi, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. 2009;49(3):9.

    View in Article

    • Google Scholar
53. • Burt A.D.
    • Lackner C.
    • Tiniakos D.G.
    Diagnosis and assessment of NAFLD: definitions and histopathological classification.
    Semin Liver Dis. 2015; 35: 207-220
    View in Article

    • Google Scholar
54. • Calderaro J.
    • Ziol M.
    • Paradis V.
    • Zucman-Rossi J.
    Molecular and histological correlations in liver cancer.
    J. Hepatol. 2019; 71: 616-630
    View in Article

    • Google Scholar
55. • Lee J.S.
    • Yoo J.E.
    • Kim H.
    • et al.
    Tumor stroma with senescence-associated secretory phenotype in steatohepatitic hepatocellular carcinoma.
    PLoS ONE. 2017; 12: e0171922
    View in Article

    • Google Scholar
56. • Shibahara J.
    • Ando S.
    • Sakamoto Y.
    • et al.
    Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients.
    Histopathology. 2014; 64: 951-962
    View in Article

    • Google Scholar
57. • Salomao M.
    • Yu W.M.
    • Brown R.S.
    • et al.
    Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
    Am J Surg Pathol. 2010; 34: 1630-1636
    View in Article

    • Google Scholar
58. • Jain D.
    Steatohepatitic hepatocellular carcinoma: a metabolic syndrome-associated carcinoma.
    Histopathology. 2015; 67: 267
    View in Article

    • Google Scholar
59. • Nascimbeni F.
    • Ballestri S.
    • Di Tommaso L.
    • et al.
    Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: chance tetrad or association by necessity?.
    Dig Liver Dis. 2014; 46: 288-289
    View in Article

    • Google Scholar
60. • Nault J.-.C.
    • Couchy G.
    • Balabaud C.
    • et al.
    Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation.
    Gastroenterology. 2017; 152 (e6): 880-894
    View in Article

    • Google Scholar
61. • Baumeister S.E.
    • Schlesinger S.
    • Aleksandrova K.
    • et al.
    Association between physical activity and risk of hepatobiliary cancers: a multinational cohort study.
    J Hepatol. 2019; 70: 885-892
    View in Article

    • Google Scholar
62. • Singh S.
    • Singh P.P.
    • Singh A.G.
    • et al.
    Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
    Am J Gastroenterol. 2013; 108 (quiz 520): 510-519
    View in Article

    • Google Scholar
63. • Strandberg T.E.
    • Pyörälä K.
    • Cook T.J.
    • et al.
    Mortality and incidence of cancer during 10-year follow-up of the scandinavian simvastatin survival study (4S).
    Lancet. 2004; 364: 771-777
    View in Article

    • Google Scholar
64. • Islam M.M.
    • Poly T.N.
    • Walther B.A.
    • Yang H.C.
    • Jack Li Y.C.
    Statin use and the risk of hepatocellular carcinoma: a meta-analysis of observational studies.
    Cancers (Basel). 2020; 12: 1-17
    View in Article

    • Google Scholar
65. • Njei B.
    • McCarty T.R.
    • Sharma P.
    • et al.
    Bariatric surgery and hepatocellular carcinoma: a propensity score-matched analysis.
    Obes Surg. 2018; 28: 3880-3889
    View in Article

    • Google Scholar
66. • Simmons O.
    • Fetzer D.T.
    • Yokoo T.
    • et al.
    Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis.
    Aliment Pharmacol Ther. 2017; 45: 169-177
    View in Article

    • Google Scholar
67. • Ioannou G.N.
    • Green P.
    • Lowy E.
    • Mun E.J.
    • Berry K.
    Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis.
    PLoS ONE. 2018; 13 (e0204412): 1-20
    View in Article

    • Google Scholar
68. • Best J.
    • Bechmann L.P.
    • Sowa J.P.
    • et al.
    GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis.
    Clin Gastroenterol Hepatol. 2020; 18: 728-735
    View in Article

    • Google Scholar
69. • Reddy S.K.
    • Steel J.L.
    • Chen H.W.
    • et al.
    Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.
    Hepatology. 2012; 55: 1809-1819
    View in Article

    • Google Scholar
70. • Cauchy F.
    • Zalinski S.
    • Dokmak S.
    • et al.
    Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome.
    Br J Surg. 2013; 100: 113-121
    View in Article

    • Google Scholar
71. • Viganò L.
    • Conci S.
    • Cescon M.
    • et al.
    Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: a multicenter matched analysis with HCV-related HCC.
    J Hepatol. 2015; 63: 93-101
    View in Article

    • Google Scholar
72. • Liang J.
    • Ariizumi S.-.I.
    • Nakano M.
    • Yamamoto M.
    Diabetes mellitus and/or nonalcoholic steatohepatitis-related hepatocellular carcinoma showed favorable surgical outcomes after hepatectomy.
    Anticancer Res. 2019; 39: 5639-5643
    View in Article

    • Google Scholar
73. • Koh Y.X.
    • Tan H.J.
    • Liew Y.X.
    • et al.
    Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma.
    J Am Coll Surg. 2019; 229: 467-478
    View in Article

    • Google Scholar
74. • Yang T.
    • Hu L.Y.
    • Li Z.L.
    • et al.
    Liver resection for hepatocellular carcinoma in non-alcoholic fatty liver disease: a multicenter propensity matching analysis with HBV-HCC.
    J Gastrointest Surg. 2020; 24: 320-329
    View in Article

    • Google Scholar
75. • Wong R.J.
    • Aguilar M.
    • Cheung R.
    • et al.
    Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.
    Gastroenterology. 2015; 148: 547-555
    View in Article

    • Google Scholar
76. • Gawrieh S.
    • Dakhoul L.
    • Miller E.
    • et al.
    Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study.
    Aliment Pharmacol Ther. 2019; 50: 809-821
    View in Article

    • Google Scholar
77. • Haldar D.
    • Kern B.
    • Hodson J.
    • et al.
    Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant registry study.
    J Hepatol. 2019; 71: 313-322
    View in Article

    • Google Scholar
78. • Bassaganyas L.
    • Pinyol R.
    • Esteban-Fabró R.
    • et al.
    Copy-number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma.
    Clin Cancer Res. 2020; 26: 6350-6361
    View in Article

    • Google Scholar
79. • Feng G.S.
    • Hanley K.L.
    • Liang Y.
    • Lin X.
    Improving the efficacy of liver cancer immunotherapy: the power of combined preclinical and clinical studies.
    Hepatology. 2021; 73: 104-114
    View in Article

    • Google Scholar
80. • Dudek M.
    • Pfister D.
    • Donakonda S.
    • et al.
    Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH.
    Nature. 2021; 592: 444-449
    View in Article

    • Google Scholar
81. • Finn R.S.
    • Qin S.
    • Ikeda M.
    • et al.
    IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
    JCO. 2021; 39 (–267): 267
    View in Article

    • Google Scholar
82. • Llovet J.M.
    • Kelley R.K.
    • Villanueva A.
    • et al.
    Hepatocellular carcinoma.
    Nat Rev Dis Primers. 2021; 7: 6
    View in Article

    • Google Scholar

83. B. Scheiner, M.M. Kirstein, F. Hucke, et al. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther 2019;49(10):1323-1333.

    View in Article

    • Google Scholar
84. • Pinter M.
    • Scheiner B.
    • Peck-Radosavljevic M.
    Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.
    Gut. 2021; 70: 204-214
    View in Article

    • Google Scholar
85. • Duffy A.G.
    • Ulahannan S.V.
    • Makorova-Rusher O.
    • et al.
    Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
    J Hepatol. 2017; 66: 545-551
    View in Article

    • Google Scholar
86. • Petta S.
    • Ting J.
    • Saragoni S.
    • et al.
    Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
    Nutr Metab Cardiovasc Dis. 2020; 30: 1014-1022
    View in Article

    • Google Scholar
87. • Lazarus J.V.
    • Ekstedt M.
    • Marchesini G.
    • et al.
    A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.
    J Hepatol. 2020; 72: 14-24
    View in Article

    • Google Scholar